Letters to the Editor

Diagnostic Criteria for Percutaneous Coronary Intervention-Related Myocardial Infarction
Time for Revision? A significant increase of cardiac biomarkers after percutaneous coronary intervention (PCI) is commonplace and is thought to reflect a clinically significant myocardial injury. According to the joint European Society of Cardiology/American College of Cardiology Foundation/American Heart Association/World Heart Federation task force for the redefinition of myocardial infarction (MI), increases of cardiac troponins Ͼ3 times the 99th percentile upper reference limit (URL) are designated as percutaneous coronary intervention (PCI)-related MI (type 4a) (1) .
We read with interest the article by Lim et al. (2) , who concluded that creatine kinase-myocardial band (CK-MB) should be the preferred biomarker when applying the current universal definition of MI to periprocedural injury, because the arbitrary limit of 3 times the 99th percentile URL troponin threshold might be oversensitive and lead to over-diagnosis of MI in as many as 53% of patients (2) . A similar conclusion was earlier reached by Locca et al. (3) , who reported a lack of substantial agreement between the new universal definition and cardiovascular magnetic resonance for the diagnosis of small-size periprocedural myocardial damage after complex PCI (3) . Although the current definition of periprocedural injury based on the Ͼ3 times the 99th percentile URL troponin value might, hence, be challenging, especially when using the new highly sensitive assays, Testa et al. (4) carried out a meta-analysis of 15 studies and 7,578 patients, concluding that troponin elevation was observed in 28.7% of patients undergoing PCI, whereas the incidence of PCI-related MI according to the new definition was 14.5% (4). Most importantly, any level of raised troponin was associated with an increased risk of the composite of all-cause death, MI, repeat target vessel PCI, and coronary artery bypass graft surgery.
Taken together, this evidence suggests that the arbitrary limit of 3 times the 99th percentile URL troponin threshold for diagnosing periprocedural injury might be urgently revised, because of 1) the unsatisfactory diagnostic specificity at this low level; and 2) the potentially inaccurate selection of the reference population for calculating the URL (5). Therefore, a higher cut-off-such as that suggested by Lim et al. (i.e., 40 times the 99th percentile)-should be used for diagnosing periprocedural MI. This enhanced threshold not only displays diagnostic performances comparable to that of CK-MB, but also overcomes the use of a double-biomarker approach (i.e., troponin and CK-MB), with a substantial economical saving. Nevertheless, the current threshold has meaningful prognostic implications, so that patients with troponin values between 3 and 40 times the 99th percentile are to be considered at risk of adverse events and should be managed accordingly.
It is also noteworthy that sample stability is critical for troponin testing. Wu et al. (6) recently observed variations in troponin I above the analytical precision cut-off (as measured with a highsensitivity assay) in 17% of short-term and 33% of long-term storage samples, suggesting that measurements are more accurate when fresh samples are used, suggesting that the definition of the optimal thresholds for both defining an increased risk of adverse events and diagnosing MI after periprocedural injury should be made preferably using fresh samples.
We are actually trapped between the Scylla of the universal definition of MI and the Charybdis of the prognostic implications of even minor troponin elevations (5 
